{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:13:09Z","timestamp":1792696389766,"version":"4.5.0"},"reference-count":50,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Lodz","award":["503\/1-090-02\/503-11-001"],"award-info":[{"award-number":["503\/1-090-02\/503-11-001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The aim of this study was to analyze the factors that may influence serum osteocalcin levels in children with osteogenesis imperfecta treated with intravenous sodium pamidronate and to define the role of osteocalcin assessment. The study included 61 patients diagnosed with osteogenesis imperfecta type 1 or 3, aged 2 to 18, hospitalized for intravenous sodium pamidronate administration. A retrospective analysis of medical records was conducted, collecting information on age, sex, body weight, height, the number of long bone fractures throughout life, serum levels of osteocalcin, creatinine, alkaline phosphatase, 25(OH)D3, and DXA BMD z-scores for the L1\u2013L4 spine segment. The concentration of osteocalcin is higher in patients with osteogenesis imperfecta than the reference ranges for sex and age. Patients diagnosed with type 3 have significantly lower osteocalcin levels compared to patients with type 1. Also, increasing the age-standardized pamidronate cycle rate significantly reduced osteocalcin concentration. The strongest predictor of osteocalcin concentration among the factors studied is the type of osteogenesis imperfecta. L1\u2013L4 BMD value and fracture frequency were unrelated to osteocalcin concentration. Osteocalcin is an important marker of bone formation that should be measured at the beginning of treatment, as its concentration decreases after successive doses of bisphosphonates.<\/jats:p>","DOI":"10.3390\/ijms26167953","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T16:22:33Z","timestamp":1755534153000},"page":"7953","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Serum Osteocalcin in Pediatric Osteogenesis Imperfecta: Impact of Disease Type and Bisphosphonate Therapy"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9483-4211","authenticated-orcid":false,"given":"Jakub Krzysztof","family":"Nowicki","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Neonatal Pathology and Metabolic Bone Diseases, Medical University of Lodz, Sporna 36\/50, 91-738 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Jakubowska-Pietkiewicz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Neonatal Pathology and Metabolic Bone Diseases, Medical University of Lodz, Sporna 36\/50, 91-738 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"w14322","DOI":"10.4414\/smw.2016.14322","article-title":"Osteogenesis imperfecta: From diagnosis and multidisciplinary treatment to future perspectives","volume":"146","author":"Pioletti","year":"2016","journal-title":"Swiss Med. Wkly."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Deguchi, M., Tsuji, S., Katsura, D., Kasahara, K., Kimura, F., and Murakami, T. (2021). Current Overview of Osteogenesis Imperfecta. Medicina, 57.","DOI":"10.3390\/medicina57050464"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00223-024-01266-5","article-title":"Update on the Genetics of Osteogenesis Imperfecta","volume":"115","author":"Jovanovic","year":"2024","journal-title":"Calcif. Tissue Int."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Paduano, F., Fischetto, R., Moretti, B., De Vito, D., and Tatullo, M. (2023). Expanding the genetic and clinical spectrum of osteogenesis imperfecta: Identification of novel rare pathogenic variants in type I collagen-encoding genes. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1254695"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"11920","DOI":"10.1038\/ncomms11920","article-title":"MBTPS2 mutations cause defective regulated intramembrane proteolysis in X-linked osteogenesis imperfecta","volume":"7","author":"Lindert","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Brlek, P., Anti\u010devi\u0107, D., Molnar, V., Mati\u0161i\u0107, V., Robinson, K., Aradhya, S., Krpan, D., and Primorac, D. (2021). X-Linked Osteogenesis Imperfecta Possibly Caused by a Novel Variant in PLS3. Genes, 12.","DOI":"10.3390\/genes12121851"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J. Med. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmg.2009.10.007","article-title":"Classification of Osteogenesis Imperfecta revisited","volume":"53","author":"Pals","year":"2010","journal-title":"Eur. J. Med. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00223-024-01248-7","article-title":"A Dyadic Nosology for Osteogenesis Imperfecta and Bone Fragility Syndromes 2024","volume":"115","author":"Sillence","year":"2024","journal-title":"Calcif. Tissue Int."},{"key":"ref_11","first-page":"31","article-title":"Determinants of survival in osteogenesis imperfecta (OI) Type II","volume":"7","author":"Nadar","year":"2019","journal-title":"Bone Abstr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/ajmg.1320170204","article-title":"Osteogenesis imperfecta type II delineation of the phenotype with reference to genetic heterogeneity","volume":"17","author":"Sillence","year":"1984","journal-title":"Am. J. Med. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1302\/0301-620X.65B1.6822598","article-title":"Osteogenesis imperfecta with dominant inheritance and normal sclerae","volume":"65","author":"Paterson","year":"1983","journal-title":"J. Bone Joint Surg. Br."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1302\/0301-620X.57B1.2","article-title":"A new look at osteogenesis imperfecta. A clinical, radiological and biochemical study of forty-two patients","volume":"57","author":"Bauze","year":"1975","journal-title":"J. Bone Joint Surg. Br."},{"key":"ref_15","unstructured":"Ganesan, K., Goyal, A., and Roane, D. (StatPearls, 2023). Bisphosphonate, StatPearls."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e10118","DOI":"10.1002\/jbm4.10118","article-title":"A Multicenter Observational Cohort Study to Evaluate the Effects of Bisphosphonate Exposure on Bone Mineral Density and Other Health Outcomes in Osteogenesis Imperfecta","volume":"3","author":"Carter","year":"2019","journal-title":"JBMR Plus"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s00774-014-0618-2","article-title":"Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age","volume":"33","author":"Kusumi","year":"2015","journal-title":"J. Bone Miner. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jbmr.2410","article-title":"Bisphosphonates for the Prevention of Fractures in Osteogenesis Imperfecta: Meta-Analysis of Placebo-Controlled Trials","volume":"30","author":"Hald","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Nijhuis, W., Verhoef, M., van Bergen, C., Weinans, H., and Sakkers, R. (2022). Fractures in Osteogenesis Imperfecta: Pathogenesis, Treatment, Rehabilitation and Prevention. Children, 9.","DOI":"10.3390\/children9020268"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"bvae163.494","DOI":"10.1210\/jendso\/bvae163.494","article-title":"6633 Romosozumab Use in a Patient With Osteogenesis Imperfecta Type 3","volume":"8","author":"Babu","year":"2024","journal-title":"J. Endocr. Soc."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.6065\/apem.2346058.029","article-title":"Denosumab use in osteogenesis imperfecta: An update on therapeutic approaches","volume":"28","author":"Majdoub","year":"2023","journal-title":"Ann. Pediatr. Endocrinol. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/07853890510007386","article-title":"Bisphosphonate treatment in osteogenesis imperfecta: Which drug, for whom, for how long?","volume":"37","author":"Rauch","year":"2005","journal-title":"Ann. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3109\/17453674.2013.831321","article-title":"Bone mineral density in developing children with osteogenesis imperfecta: A longitudinal study with 9 years of follow-up","volume":"84","author":"Kok","year":"2013","journal-title":"Acta Orthop."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/jbmr.5650090918","article-title":"Bone mineral density of total body, spine, and femoral neck in children and young adults: A cross-sectional and longitudinal study","volume":"9","author":"Lu","year":"1994","journal-title":"J. Bone Miner. Res."},{"key":"ref_25","first-page":"305","article-title":"Effects of metal implants on whole-body dual-energy x-ray absorptiometry measurements of bone mineral content and body composition","volume":"54","author":"Giangregorio","year":"2003","journal-title":"Can. Assoc. Radiol. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11657-020-00715-6","article-title":"Effects of age and sex on osteocalcin and bone-specific alkaline phosphatase-reference intervals and confounders for two bone formation markers","volume":"15","author":"Diemar","year":"2020","journal-title":"Arch. Osteoporos."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/000456329703400609","article-title":"Changes in Serum Osteocalcin Levels in the Follow-Up of Kidney Transplantation","volume":"34","author":"Bonnin","year":"1997","journal-title":"Ann. Clin. Biochem. Int. J. Biochem. Lab. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1055\/a-0752-4615","article-title":"Association Between Plasma Concentration of Klotho Protein, Osteocalcin, Leptin, Adiponectin, and Bone Mineral Density in Patients with Chronic Kidney Disease","volume":"50","author":"Wisniewska","year":"2018","journal-title":"Horm. Metab. Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Moser, S.C., and van der Eerden, B.C.J. (2018). Osteocalcin\u2014A Versatile Bone-Derived Hormone. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00794"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.mce.2013.10.008","article-title":"Regulation of male fertility by the bone-derived hormone osteocalcin","volume":"382","author":"Karsenty","year":"2014","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1007\/s00198-016-3501-2","article-title":"Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: The role of DKK1, RANKL, and TNF-\u03b1","volume":"27","author":"Brunetti","year":"2016","journal-title":"Osteoporos. Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bone.2004.02.023","article-title":"Bone turnover markers in patients with osteogenesis imperfecta","volume":"34","author":"Braga","year":"2004","journal-title":"Bone"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nature02079","article-title":"Bone recognition mechanism of porcine osteocalcin from crystal structure","volume":"425","author":"Hoang","year":"2003","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0168-9525(03)00176-8","article-title":"Transcriptional mechanisms in osteoblast differentiation and bone formation","volume":"19","author":"Nakashima","year":"2003","journal-title":"Trends Genet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S8756-3282(00)00269-6","article-title":"Static and dynamic bone histomorphometry in children with osteogenesis imperfecta","volume":"26","author":"Rauch","year":"2000","journal-title":"Bone"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1111\/j.1651-2227.2010.01968.x","article-title":"Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta","volume":"99","author":"Magnusson","year":"2010","journal-title":"Acta Paediatr."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11657-011-0054-z","article-title":"Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta","volume":"6","author":"Wekre","year":"2011","journal-title":"Arch. Osteoporos."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Erlebacher, A., and Derynck, R. (1996). Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J. Cell Biol., 132.","DOI":"10.1083\/jcb.132.1.195"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000055910","article-title":"Increased Cell Surface Expression of Receptors for Transforming Growth Factor-\u03b2 on Osteoblasts from Patients with Osteogenesis imperfecta","volume":"68","author":"Gebken","year":"2001","journal-title":"Pathobiology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nm.3544","article-title":"Excessive TGF\u03b2 signaling is a common mechanism in Osteogenesis Imperfecta","volume":"20","author":"Grafe","year":"2014","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/03009739109179272","article-title":"Short-term Effects of Pamidronate on Biochemical Markers of Bone Metabolism in Osteoporosis\u2014A Placebo-controlled Dose-finding Study","volume":"96","author":"Mallmin","year":"1991","journal-title":"Upsala J. Med Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.11005\/jbm.2013.20.1.37","article-title":"Changes in Serum Osteocalcin are Not Associated with Changes in Glucose or Insulin for Osteoporotic Patients Treated with Bisphosphonate","volume":"20","author":"Hong","year":"2013","journal-title":"J. Bone Metab."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Zheng, W.-B., Hu, J., Zhao, D.-C., Zhou, B.-N., Wang, O., Jiang, Y., Xia, W.-B., Xing, X.-P., and Li, M. (2022). The role of osteocalcin in regulation of glycolipid metabolism and muscle function in children with osteogenesis imperfecta. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.898645"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00198-005-2025-y","article-title":"Changes in bone mass and bone turnover following tibial shaft fracture","volume":"17","author":"Veitch","year":"2006","journal-title":"Osteoporos. Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_46","unstructured":"(2025, May 14). WHO Child Growth Standards: Length\/Height-for-Age, Weight-for-Age, Weight-for-Length, Weight-for-Height and Body Mass Index-for-Age: Methods and Development. Available online: https:\/\/www.who.int\/publications\/i\/item\/924154693X."},{"key":"ref_47","first-page":"690","article-title":"Percentile Charts of Height, Body Mass and Body Mass Index in Children and adolescents in Poland\u2014Results of the OLAF Study","volume":"7","author":"Kulaga","year":"2010","journal-title":"Stand. Med."},{"key":"ref_48","first-page":"599","article-title":"Polish 2010 growth references for school-aged children and adolescents","volume":"170","author":"Litwin","year":"2011","journal-title":"J. Pediatr."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00431-013-1954-2","article-title":"Polish 2012 Growth References for Preschool Children","volume":"172","author":"Grajda","year":"2013","journal-title":"Eur. J. Pediatr."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1542\/peds.58.2.259","article-title":"A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine","volume":"58","author":"Schwartz","year":"1976","journal-title":"Pediatrics"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/16\/7953\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:29:53Z","timestamp":1760034593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/16\/7953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":50,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["ijms26167953"],"URL":"https:\/\/doi.org\/10.3390\/ijms26167953","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]}}}